Serina Therapeutics, Inc. Proceeds from Common Stock Issued
Serina Therapeutics, Inc. (SER) reported Proceeds from Common Stock Issued of $4.92 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-05-08
- Serina Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $4.92M.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2021-12-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2021-09-30 was $0.00.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2021 was $496.00K.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2018 was $5.00M, a 50.00% decline from fiscal 2017.
- Serina Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2017 was $10.00M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $4.92M 10-Q · filed 2025-05-08 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | ||||
| 2023-07-31 | $25.00M 10-Q · filed 2023-11-14 | ||||
| 2023-03-13 | $25.00M 10-Q · filed 2023-08-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $496.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $496.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $496.00K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $496.00K 10-Q · filed 2022-05-13 | ||||
| 2018-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $0.00 derived: sum of 2 quarters · filed 2020-03-31 | $5.00M 10-K/A · filed 2020-03-31 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $5.00M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $5.00M 10-Q · filed 2019-08-14 | ||||
| 2017-12-31 | $10.00M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |